Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Biomed Chromatogr ; 35(3): e5016, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33125740

RESUMO

Recently the Salvia Miltiorrhiza-Moutan Cortex (SM-MC) herb pair is considered as a promising Chinese medicinal mixture exhibiting a range of pharmacological activities, including treating cardiovascular disease due to its unique composition. In this study, we conducted the comparative pharmacokinetic analysis of seven main bioactive components of SM-MC in a different model rat. A straightforward ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) strategy that could simultaneously evaluate the levels of seven compounds was used to ensure the reliability of these pharmacokinetic analyses in rat plasma. The rat plasma samples were collected from normal, sham-operated, and myocardial ischemia-reperfusion injury (MIRI) groups at predetermined time points after the administration of SM-MC. The main pharmacokinetic parameters were detected and calculated. We successfully assessed the maximum concentration (Cmax ), time to Cmax (Tmax ), the elimination rate constant (λz ), total half-life (t1/2 ), total body clearance (CL), and the area under the concentration-time curve from 0 to last sampling time (AUC0-t ) and extrapolated to infinity (AUC0-∞ ). To sum up, an optimized UPLC-MS/MS approach that could be used to rapidly, simultaneously, and sensitively detect seven bioactive compounds derived from SM-MC extract preparations was successfully developed, which may offer a pharmacokinetic basis for preclinical and clinical studies of SM-MC herb pair for treating MIRI.


Assuntos
Medicamentos de Ervas Chinesas , Traumatismo por Reperfusão Miocárdica/metabolismo , Paeonia , Salvia miltiorrhiza , Abietanos/sangue , Abietanos/farmacocinética , Ácidos Carbocíclicos/sangue , Ácidos Carbocíclicos/farmacocinética , Administração Oral , Alcenos/sangue , Alcenos/farmacocinética , Animais , Cromatografia Líquida de Alta Pressão/métodos , Medicamentos de Ervas Chinesas/administração & dosagem , Medicamentos de Ervas Chinesas/farmacocinética , Modelos Lineares , Masculino , Polifenóis/sangue , Polifenóis/farmacocinética , Ratos , Ratos Sprague-Dawley , Reprodutibilidade dos Testes , Sensibilidade e Especificidade
2.
Biomed Pharmacother ; 129: 110464, 2020 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-32768954

RESUMO

Peramivir, a neuraminidase inhibitor, was approved globally and is indicated for the treatment of uncomplicated influenza in adults and children. However, the only approved intravenous formulation of peramivir limits its clinical application due to the need for the specialized dosing techniques and increases the risk of contracting influenza virus infection among healthcare professionals when dosing within a short distance to the patient. The purpose of this study was to investigate the pharmacokinetic profile of peramivir in plasma and the lung of rats and to compare the profiles following administration through trans-nasal aerosol inhalation (0.0888, 0.1776, and 0.3552 mg/kg) and intravenous injection (30 mg/kg). The plasma concentration reached the Cmax within 1.0 h (upon inhalation) and decreased at a t1/2 of 6.71 and 10.9 h after inhalation and injection, respectively. The absolute bioavailability of peramivir after inhalation was 78.2 %. Overall, the pharmacokinetic exposure of peramivir in the lungs was higher than that in the plasma after aerosol inhalation. After inhalation, the Cmax of peramivir in the lung was achieved within 1.0 h, and the elimination of the drug was slower than in the case of intravenous injection with t1/2 values 1.81 h for injection and 5.72, 53.5, and 32.1 h for low, middle, and high doses administered through inhalation. The Cmax and AUC0-t values for peramivir in the lungs increased linearly with the increased inhalation dose. The results elucidate the pharmacokinetic process of peramivir after trans-nasal aerosol inhalation to rats and provide useful information for further rational application of this drug formulation.


Assuntos
Ácidos Carbocíclicos/administração & dosagem , Ácidos Carbocíclicos/farmacocinética , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/farmacocinética , Guanidinas/administração & dosagem , Guanidinas/farmacocinética , Pulmão/metabolismo , Ácidos Carbocíclicos/sangue , Administração por Inalação , Aerossóis , Animais , Disponibilidade Biológica , Inibidores Enzimáticos/sangue , Guanidinas/sangue , Meia-Vida , Injeções Intravenosas , Masculino , Taxa de Depuração Metabólica , Neuraminidase/antagonistas & inibidores , Ratos Sprague-Dawley , Distribuição Tecidual
3.
Molecules ; 18(5): 5420-33, 2013 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-23666008

RESUMO

A series of new matrinic acid derivatives 5a-e was synthesized. The chemical structures of the synthesized compounds were confirmed by ¹H-NMR, ¹³C-NMR, and electrospray ionization mass spectroscopy. The anti-tumor activities were also investigated in vitro by evaluating the effect of synthesized compounds on the proliferation of A375, A549, HeLa, and HepG2 cells. Compound 5e was found to be the most potent against A375 and HeLa cells, with IC50 values of 37 and 75.5 µg/mL, respectively. Compounds 5b, 5c, 5g, and 5h also exhibited antiproliferative activities against A549 cells, with IC50 values within the 36.2-47 µg/mL range. For HepG2 cells, 5e and 5i, with IC50 values of 78.9 and 61 µg/mL, respectively, showed higher antiproliferative activity than taxol.


Assuntos
Ácidos Carbocíclicos , Alcaloides , Antineoplásicos , Proliferação de Células/efeitos dos fármacos , Quinolizinas , Ácidos Carbocíclicos/síntese química , Ácidos Carbocíclicos/química , Ácidos Carbocíclicos/farmacocinética , Antineoplásicos/síntese química , Antineoplásicos/química , Antineoplásicos/farmacologia , Ensaios de Seleção de Medicamentos Antitumorais , Células HeLa , Células Hep G2 , Humanos , Matrinas
4.
Am J Chin Med ; 41(3): 697-715, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23711150

RESUMO

We developed a sensitive and rapid method for determination of ferulic acid, caffeic acid, vanillic acid, and paeoniflorin in rat plasma based on ultra high performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS). The separation of the four compounds was carried out on an AcQuity UHPLC™ BEH C18 column using a mobile phase consisting of acetonitrile and water (containing 0.1% formic acid). Electrospray ionization in positive and negative ion mode and multiple reaction monitoring was used to identify and quantify active components. All calibration curves gave good linearity (r > 0.991) over the concentration range from 4.24-2875 ngmL(-1) for all components. The precision of the in vivo study was evaluated by intraday and interday assays and the percentages of RSD were all within 10.6%. The recovery ranged from 60.2 to 77.9%. The method was successfully applied to pharmacokinetic study of all three aromatic acids and one monoterpene in rat plasma. Furthermore, we compared the pharmacokinetics profile of the four compounds in normal and primary dysmenorrhea rats' plasma following oral administration of Shaofu Zhuyu decoction (SFZYD) and its ethanol supernatant extract (SFE).


Assuntos
Ácidos Carbocíclicos/farmacocinética , Benzoatos/farmacocinética , Hidrocarbonetos Aromáticos com Pontes/farmacocinética , Cromatografia Líquida de Alta Pressão/métodos , Medicamentos de Ervas Chinesas/farmacocinética , Dismenorreia/sangue , Glucosídeos/farmacocinética , Monoterpenos/farmacocinética , Espectrometria de Massas em Tandem/métodos , Ácidos Carbocíclicos/sangue , Administração Oral , Animais , Benzoatos/sangue , Hidrocarbonetos Aromáticos com Pontes/sangue , Ácidos Cafeicos/sangue , Ácidos Cafeicos/farmacocinética , Ácidos Cumáricos/sangue , Ácidos Cumáricos/farmacocinética , Medicamentos de Ervas Chinesas/química , Feminino , Glucosídeos/sangue , Monoterpenos/sangue , Ratos , Ratos Sprague-Dawley , Espectrometria de Massas por Ionização por Electrospray/métodos , Ácido Vanílico/sangue , Ácido Vanílico/farmacocinética
5.
J Agric Food Chem ; 54(20): 7539-43, 2006 Oct 04.
Artigo em Inglês | MEDLINE | ID: mdl-17002419

RESUMO

The intestinal absorption characteristics of phenolic acids (PAs) have been elucidated in terms of their affinity for the monocarboxylic acid transporter (MCT). Recently, the involvement of the stomach has been implicated in the absorption of polyphenols. The present work demonstrates that the gastric absorption efficiency of each PA is apparently different between various PAs. Various PAs with different affinities for MCT were administered (2.25 mumol) to rat stomach, and then the plasma concentration of the PA was measured. The plasma concentration of ferulic acid (FA) peaked 5 min after administration in the stomach. At 5 min after administration, the plasma concentration of each PA increased in the order: gallic acid = chlorogenic acid < caffeic acid < p-coumaric acid = FA. This order matches their respective affinity for MCT in Caco-2 cells, which we have demonstrated in previous studies. These results indicated that MCT might be involved in the gastric absorption of PAs, similar to the intestinal absorption.


Assuntos
Ácidos Carbocíclicos/farmacocinética , Mucosa Gástrica/metabolismo , Absorção , Ácidos Carbocíclicos/sangue , Animais , Aorta Abdominal , Ácidos Cumáricos/sangue , Ácidos Cumáricos/farmacocinética , Cinética , Masculino , Transportadores de Ácidos Monocarboxílicos/metabolismo , Veia Porta , Ratos , Ratos Wistar
6.
J Med Chem ; 49(14): 4409-24, 2006 Jul 13.
Artigo em Inglês | MEDLINE | ID: mdl-16821800

RESUMO

Female sexual arousal disorder (FSAD) is a highly prevalent sexual disorder affecting up to 40% of women. We describe herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential treatment for FSAD. The rationale for this approach, together with a description of the medicinal chemistry strategy, lead compounds, and SAR investigations are detailed. In particular, the strategy of starting with the clinically precedented selective NEP inhibitor, Candoxatrilat, and targeting low molecular weight and relatively polar mono-carboxylic acids is described. This led ultimately to the prototype development candidate R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.(1)


Assuntos
Ácidos Carbocíclicos/síntese química , Amidas/síntese química , Neprilisina/antagonistas & inibidores , Ácidos Pentanoicos/síntese química , Disfunções Sexuais Psicogênicas/tratamento farmacológico , Tiadiazóis/síntese química , Ácidos Carbocíclicos/farmacocinética , Ácidos Carbocíclicos/farmacologia , Amidas/farmacocinética , Amidas/farmacologia , Animais , Células CHO , Clitóris/irrigação sanguínea , Clitóris/efeitos dos fármacos , Cricetinae , Cricetulus , Cães , Feminino , Humanos , Masculino , Ácidos Pentanoicos/farmacocinética , Ácidos Pentanoicos/farmacologia , Piridinas/síntese química , Piridinas/farmacocinética , Piridinas/farmacologia , Coelhos , Ratos , Proteínas Recombinantes/antagonistas & inibidores , Fluxo Sanguíneo Regional/efeitos dos fármacos , Especificidade da Espécie , Estereoisomerismo , Relação Estrutura-Atividade , Tiadiazóis/farmacocinética , Tiadiazóis/farmacologia , Vagina/irrigação sanguínea , Vagina/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA